1. Home
  2. SO vs GLSI Comparison

SO vs GLSI Comparison

Compare SO & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Company (The)

SO

Southern Company (The)

HOLD

Current Price

$94.63

Market Cap

99.2B

Sector

Utilities

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$26.74

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SO
GLSI
Founded
1946
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.2B
123.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SO
GLSI
Price
$94.63
$26.74
Analyst Decision
Hold
Strong Buy
Analyst Count
16
1
Target Price
$94.03
$50.00
AVG Volume (30 Days)
6.3M
639.1K
Earning Date
02-19-2026
11-14-2025
Dividend Yield
3.20%
N/A
EPS Growth
N/A
N/A
EPS
4.02
N/A
Revenue
$28,913,000,000.00
N/A
Revenue This Year
$10.02
N/A
Revenue Next Year
$5.19
N/A
P/E Ratio
$23.01
N/A
Revenue Growth
9.40
N/A
52 Week Low
$83.09
$7.78
52 Week High
$100.84
$34.10

Technical Indicators

Market Signals
Indicator
SO
GLSI
Relative Strength Index (RSI) 66.74 50.41
Support Level $88.84 $25.68
Resistance Level $93.26 $30.13
Average True Range (ATR) 1.50 3.14
MACD 0.32 -0.80
Stochastic Oscillator 89.79 20.84

Price Performance

Historical Comparison
SO
GLSI

About SO Southern Company (The)

Southern is one of the largest utilities in the US. The company serves 9 million customers with vertically integrated electric utilities in three states and natural gas distribution utilities in four states. It owns 44 gigawatts of rate-regulated generating capacity, primarily for serving customers in Georgia, Alabama, and Mississippi. Subsidiary Southern Power owns 13 gigawatts of natural gas generation and renewable energy across the US and sells the electricity primarily under long-term contracts.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: